Huntington disease

Related records

Broader conditions (13)

• Central nervous system disorder
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Disease of genetic or genomic mechanism
• Hereditary disease
• Hereditary neurological disease
• Human disease
• Huntington disease and related disorders
• Inherited neurodegenerative disorder
• Movement disorder
• Nervous system disorder
• Neurodegenerative disease

Narrower conditions (2)

• Juvenile Huntington disease
• Westphal disease

Trials (297)

• [PETDE10] Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls With PET.
• 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
• 31P-MRS and Huntington Disease
• A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery
• A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod
• A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease
• A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease
• A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects
• A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
• A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease
• A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions
• A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan
• A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects
• A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
• A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
• A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease
• A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease.
• A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers
• A Phase II Safety and Tolerability Study With SEN0014196
• A Pilot Evaluation of Mindfulness-based Cognitive Therapy for People With Huntington's Disease

Approved drugs (2)

• Deutetrabenazine
• Tetrabenazine

Drugs in development (50)

• Acetylcysteine Phase 2
• ANX-005 Phase 2
• Bevantolol hydrochloride Phase 2
• Biotin Phase 2
• Branaplam Phase 2
• Branaplam hydrochloride Phase 1
• Bupropion Phase 2
• Cannabidiol Phase 2
• Cannabinol Phase 2
• Creatine Phase 3
• Dalzanemdor Phase 3
• Divalproex sodium Phase 2
• Epigalocatechin gallate Phase 2
• Fenofibrate Phase 2
• GSK-356278 Phase 1
• Haloperidol Phase 1
• Idebenone Phase 1
• Laquinimod Phase 2
• Latrepirdine Phase 3
• Lexanersen Phase 1

Other linked drugs (5)

• Atomoxetine hydrochloride
• Cysteamine bitartrate
• Guanfacine hydrochloride
• Lisdexamfetamine dimesylate
• Methylphenidate hydrochloride